FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling eligible patients.read more...
Benzinga
More News
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.
Zacks
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs...